
Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter. Arcturus Therapeutics collected $5.79 million in revenue during Q4, but reported earnings showed a $38.66 million loss.